Latest Breaking News On - Umiami miller school of medicine - Page 4 : comparemela.com
Clarkson University and Ichor Therapeutics Partner to Establish Biotechnology Cluster in North Country
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ichor Therapeutics Inc expands to North Country Incubator in Potsdam
northcountrynow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northcountrynow.com Daily Mail and Mail on Sunday newspapers.
Clarkson University and Ichor Therapeutics Partner to
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Hyderabad varsity startup develops stem cell-based treatment for Covid
Top Searches:
IANS | Updated: May 4, 2021, 09:46 IST
A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
Picture used for representational purpose only
HYDERABAD: A biotech startup company, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), on Monday announced a human umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy for Covid patients.
Transcell Oncologics has developed a proprietary cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics
A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics,
a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday.
The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients.